Overview of FLAURA and MARIPOSA-2 Clinical Trials

August 19th 2025

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

Jacob Sands, MD

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Sanan Rasheed, MBBS;Umer Farooq, MBBS;Aiman Waheed, MBBS;Musharaf Khalid Bhutta, MBBS;Adnan Bhat, MD;Hamza Nazir, MBBS;Muhammad Hamza Gul, MBBS, MD;Ayesha Aman, MBBS;Zainab Ibrahim, MBBS;Abdul Baseer Wardak, MBBS

August 14th 2025

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Zongertinib Earns FDA Accelerated Approval in HER2+ NSCLC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

August 8th 2025

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Zongertinib is now approved by the FDA for patients with nonsquamous NSCLC with HER2 TKD activating mutations.

Roman Fabbricatore

Emotional Distress May Confer Worse Immunotherapy Outcomes in NSCLC

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Related Content

August 19th 2025

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

Jacob Sands, MD

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

August 14th 2025

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Zongertinib Earns FDA Accelerated Approval in HER2+ NSCLC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

August 8th 2025

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Zongertinib is now approved by the FDA for patients with nonsquamous NSCLC with HER2 TKD activating mutations.

Roman Fabbricatore